Education
About Us
Working with TipRanks
Follow Us
Mereo Biopharma Group Plc (MREO)
NASDAQ:MREO
MREO Stock Chart & Stats
$1.76
-$0.02(-0.40%)
At close: 4:00 PM EST
$1.76
-$0.02(-0.40%)
Day’s Range― - ―
52-Week Range$1.47 - $4.40
Previous CloseN/A
Volume219.93K
Average Volume (3M)1.52M
Market Cap
$286.20M
Enterprise Value$377.77M
Total Cash (Recent Filing)$56.13M
Total Debt (Recent Filing)$601.00K
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Nov 18, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding159,096,880
10 Day Avg. Volume1,559,022
30 Day Avg. Volume1,519,079
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue241.50
Enterprise Value/Gross Profit1.10K
Enterprise Value/Ebitda-8.08
Forecast
1Y Price Target
$7.20Price Target Upside309.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$27.83M
Bulls Say, Bears Say
Bulls Say
Financial StrengthMREO ended with $56.1M cash, which the company is guiding as sufficient to fund operations into 2027.
Market OpportunityThere is a significant opportunity for setrusumab in osteogenesis imperfecta if approved, with feedback suggesting even a modest reduction in fractures would be well received.
PartnershipsMREO is actively engaged with multiple potential partners regarding development and commercialization of alvelestat.
Bears Say
Trial ResultsThe second interim analysis of Orbit did not meet the primary endpoint of annualized fracture rate reduction at the pre-specified threshold.
Mereo Biopharma Group Plc News
MREO FAQ
What was Mereo Biopharma Group Plc’s price range in the past 12 months?
Mereo Biopharma Group Plc lowest stock price was $1.47 and its highest was $4.39 in the past 12 months.
What is Mereo Biopharma Group Plc’s market cap?
Mereo Biopharma Group Plc’s market cap is $286.20M.
When is Mereo Biopharma Group Plc’s upcoming earnings report date?
Mereo Biopharma Group Plc’s upcoming earnings report date is Nov 18, 2025 which is in 10 days.
How were Mereo Biopharma Group Plc’s earnings last quarter?
Mereo Biopharma Group Plc released its earnings results on Aug 12, 2025. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of -$0.012 by -$0.008.
Is Mereo Biopharma Group Plc overvalued?
According to Wall Street analysts Mereo Biopharma Group Plc’s price is currently Undervalued.
Does Mereo Biopharma Group Plc pay dividends?
Mereo Biopharma Group Plc does not currently pay dividends.
What is Mereo Biopharma Group Plc’s EPS estimate?
Mereo Biopharma Group Plc’s EPS estimate is >-0.01.
How many shares outstanding does Mereo Biopharma Group Plc have?
Mereo Biopharma Group Plc has 159,096,880 shares outstanding.
What happened to Mereo Biopharma Group Plc’s price movement after its last earnings report?
Mereo Biopharma Group Plc reported an EPS of -$0.02 in its last earnings report, missing expectations of -$0.012. Following the earnings report the stock price went up 9.211%.
Which hedge fund is a major shareholder of Mereo Biopharma Group Plc?
Currently, no hedge funds are holding shares in MREO
Mereo Biopharma Group Plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.20 (309.09% Upside)
$7.20 (309.09% Upside)
Blogger Sentiment
Bullish
MREO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.07%
12-Months-Change
Fundamentals
Return on Equity
-75.08%
Trailing 12-Months
Asset Growth
-34.85%
Trailing 12-Months
Company Description
Mereo Biopharma Group Plc
Mereo BioPharma Group Plc (MREO) is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of rare and specialty diseases. The company's pipeline includes multiple clinical-stage programs across various therapeutic areas such as oncology, respiratory, and rare diseases. Mereo BioPharma aims to address unmet medical needs through its proprietary drug candidates, leveraging strategic partnerships and collaborations to advance its research and development efforts.
MREO Stock 12 Month Forecast
Average Price Target
$7.20
▲(309.09% Upside)
Technical Analysis
Ownership Overview
1.32%
Insiders
1.04% Mutual Funds
0.01% Other Institutional Investors
97.25% Public Companies and
Individual Investors